No abstract

clinical outcome in children aged 2-59 months with WHO-defined nonsevere pneumonia is not different when treated with an antibiotic or placebo. Similar trials are needed in countries with a high burden of pneumonia to rationalize the use of antibiotics in these communities.

Clinical outcome in children aged 2-59 months with non-severe pneumonia is the same with standard and double dose oral amoxicillin. Non-severe pneumonia can be treated effectively and safely with a 3 day course of a standard dose.

No abstract

Childhood acute lymphoblastic leukemia tients were 2-10 years of age and 3 were older (ALL) has a 5-year disease-free survival (DFS) of than 10 years. Male to female ratio was 3.2:1. more than 70%. This fact is not reflected in 71.4% had L1 and 28.6% had L2 morphology. developing countries due to the lack of proper Univariate analysis factors revealed central nersupportive care. A modified version of the stan-vous system (CNS) involvement and late comdard Berlin-Frankfurt-Munich (BFM) protocol plete remission (CR) during induction as poor for pediatric ALL was developed to achieve balprognostic factors. In multivariate analysis, CNS ance between toxicity and favorable response disease (P Ͻ 0.0083) was the only prognostic rates. Modification included a dose reduction variable for prolonged DFS. All patients went of asparaginase and methotrexate during the into CR. Eleven patients have relapsed. Life table consolidation and reinduction phase. Forty-two analysis of these patients shows a 59.4% probapatients younger than 15 years of age were put bility of overall survival (OS) and a 52.5% probaon the modified BFM protocol between Novembility of DFS at 48 months. ᮊ 1997 Wiley-Liss, Inc. ber 1990 and November 1993. Thirty-nine pa-